Please ensure Javascript is enabled for purposes of website accessibility

If You Thought Snowflake's IPO Was Exciting, You'll Want To Watch This Healthcare Tech Stock

By Eric Volkman – Sep 22, 2020 at 4:05PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

GoodRx is successful, profitable, and going public on Wednesday.

The recent flood of IPOs is threatening to submerge the stock market. One that's standing out like a life raft is GoodRx, a company with a unique business model and several other attributes that are sure to draw a lot of investor attention.

Its core product is a price-searching service for prescription medications, which it offers through a dedicated smartphone app. The company is paid a percentage of every sale, hewing to the classic middleman business model.

GoodRx's aim is to utilize this platform to offer a host of other healthcare services. One of these is a telemedicine product, HeyDoctor, which is roughly comparable to that of Teladoc Health (TDOC -2.04%). Teladoc has been a standout performer this year thanks to the wild popularity of telemedicine as a segment; GoodRx management is smart to play up the company's involvement in that healthcare niche.

Elderly person at a table with bottles of pills.

Image source: Getty Images.

At the moment, though, prescription commissions account for the vast majority of its revenues -- 94% in 2019. It's clearly a strong core product -- overall top line grew at a 56% year-over-year clip last year (although acquisitions have also contributed to that expansion). Also,  GoodRx is one of the rare tech-leaning start-ups that's profitable. Its annual net margins over the last three years have been around 17% to 18%.

It remains to be seen how the company will fare in other segments, notably telemedicine, where competition is heating up to the boiling point. Still, its robust prescription business and high profitability should make it a popular stock from the get-go.

GoodRx is slated to begin trading on the Nasdaq Wednesday under the ticker symbol GDRX. In the IPO, the company is selling just over 23.4 million shares of Class A common stock; current shareholders are divesting nearly 11.2 million more. The price range has been set at $24 to $28 per share.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Teladoc Health. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teladoc Health, Inc. Stock Quote
Teladoc Health, Inc.
$26.42 (-2.04%) $0.55

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.